August 22, 2025

Evidence of Potential Cure With Single CAR T-Cell Infusion for Some Patients With Multiple Myeloma

In long-term results from the CARTITUDE-1 trial, investigators had found that the autologous cellular immunotherapy ciltacabtagene autoleucel was potentially curative for one-third of patients with he...

The ASCO Post

August 22, 2025

Linear Hyperpigmentation After Chemotherapy: What's Your Diagnosis?

A 15-year-old girl developed distinctive, painless, whip-like streaks across her trunk and back after receiving combination chemotherapy for ovarian yolk sac tumor. What’s your diagnosis?

Conexiant

August 22, 2025

Pediatric Gliomas: Early Research on Targeted Therapies

“[These are] the first preclinical data showing that existing FGFR inhibitors might be viable therapeutics for FGFR-altered pediatric gliomas.”

The ASCO Post

August 22, 2025

Outcomes Associated With COVID-19 Infection in Patients With Cancer

“The results of this prospective cohort study showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.”

The ASCO Post

August 22, 2025

Pediatric CNS Tumors: Long-Term Survival and Cure Fraction Estimates

As reported in The Lancet Oncology by Hoogendijk et al, the EUROCARE-6 population-based study has provided long-term survival rates and cure fraction estimates for pediatric patients with central nerv...

The ASCO Post

August 12, 2025

Advanced-Practice Providers Filling Rural ER Gaps

Rural emergency rooms across the U.S. are increasingly staffed by physician assistants and nurse practitioners instead of physicians, raising debates over care quality, staffing shortages, and access to emergency services.

KFF Health News

August 11, 2025

FDA OKs Bioequivalent Iron Sucrose for CKD Anemia

The FDA has approved a bioequivalent iron sucrose injection for treating iron deficiency anemia in patients with chronic kidney disease.

Conexiant

August 11, 2025

Why Turning 26 Jeopardizes Health Coverage

A growing number of young Americans lose affordable health insurance at age 26, facing complex Affordable Care Act marketplaces, rising costs, and limited coverage options.

KFF Health News

August 06, 2025

Protease Activator Approved by the FDA for Diffuse Midline Glioma

This represents the first FDA approval of a systemic therapy for H3 K27M–mutant diffuse midline glioma.

The ASCO Post